Workflow
子宫内膜异位症治疗
icon
Search documents
长春高新:伏欣奇拜单抗注射液临床试验申请获批
news flash· 2025-04-28 08:56
Core Viewpoint - Changchun High-tech (000661) announced that its subsidiary, Jinsai Pharmaceutical, received approval from the National Medical Products Administration for the clinical trial application of Fuxin Qibai monoclonal antibody injection, which is a first-class new drug for the treatment of endometriosis [1] Company Summary - Jinsai Pharmaceutical is developing Fuxin Qibai monoclonal antibody injection, which is a self-developed biological product aimed at treating endometriosis [1] - The drug specifically blocks the binding of IL-1β to its receptor IL-1R, thereby inhibiting the activation of downstream signaling pathways associated with the receptor [1] - The approval of the clinical trial application will facilitate the subsequent clinical development of this product and further meet the clinical needs of patients [1] Industry Summary - Endometriosis is a common chronic systemic inflammatory disease with an incidence rate of approximately 10%-15% and is prone to recurrence, requiring long-term management [1] - The successful development of new treatments like Fuxin Qibai monoclonal antibody injection could significantly impact the management of endometriosis and improve patient outcomes [1]